Determination of endothelial progenitor cells in peripheral blood of breast cancer patients

doi:10.3877/cma.j.issn.1674-0807.2018.05.003

Abstract

Abstract:

Objective

To investigate the clinical significance of endothelial progenitor cells (EPCs) in peripheral blood of breast cancer patients.

Methods

Peripheral blood from healthy volunteers (control group, n=68), breast fibroadenoma patients (benign group, n=61) and patients with invasive ductal breast cancer (n=70) in Jilin Cancer Hospital from March 2014 to March 2015 were collected for a prospective study. The concentration of EPCs (marked by CD34, CD133 and VEGFR-2 positive) was determined by flow cytometry. Fisher’s exact probability test and Kruskal-Wallis H test were used to compare the positive rate of EPCs and the expression of CD34, CD133 and VEGFR-2 among three groups. Fisher’s exact probability test was used to analyze the relationship between the positive rate of EPCs and clinicopathological features in breast cancer patients. The expression of CD34, CD133 and VEGFR-2 (surface markers of EPCs) was compared in the patients with different clinical stages and lymph node metastasis status by t test.

Results

The positive rate of EPCs and the expression of CD34, CD133 and VEGFR-2 presented a significant difference among three groups (χ²=12.811, P<0.001; F=15.275, P<0.001). EPCs were not detected in control group and benign group. The expression of CD34, CD133 and VEGFR-2 in breast cancer group was 0.006%(0.003%-0.008%)[M(P₂₅-P₇₅)], significantly higher than that in control group or benign group (P=0.002 and P=0.003). The positive rate of EPCs was significantly higher than that in control group or benign group [11.4% (8/70) vs 0 (0/68), P=0.006; 11.4% (8/70) vs 0 (0/61), P=0.007]. The positive rate of EPCs was not correlated with patient age, ER, PR and HER-2 status (all P>0.05). In eight breast cancer patients with EPCs positive, the expression of CD34, CD133 and VEGFR-2 in stageⅠbreast cancer was significantly lower than that in stage Ⅱ-Ⅳ breast cancer [(0.300±0.162)% vs (1.130±0.318)%, t=4.640, P=0.004), and the expression of CD34, CD133 and VEGFR-2 in patients with lymph node metastasis was significantly higher than that in patients without [(1.062±0.424)% vs (0.370±0.287)%, t=2.700, P=0.040].

Conclusion

CD34, CD133 and VEGFR-2(surface markers of EPCs) have high expression in peripheral blood of breast cancer patients, so EPCs might serve as a potential biomarker and a therapeutic target.

Key words: Breast neoplasms, Endothelium, blood vessels, Endothelial growth factor receptor-2, Antigens, CD, Endothelial progenitor cells

Jiaming Wang, Gang Wei, Zhen Ma, Changqing Wang, Shi Yan, Yan Liu, Hui Li. Determination of endothelial progenitor cells in peripheral blood of breast cancer patients[J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(05): 270-275.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2018.05.003

https://zhrxbzz.cma-cmc.com.cn/EN/Y2018/V12/I05/270

Figures/Tables 5

References 23

[1]	王殊. 2017年美国临床肿瘤学会年会乳腺癌研究进展回顾：加减均是精准路上的一步[J/CD]. 中华乳腺病杂志(电子版), 2017, 11(6): 321-324.
[2]	Estes ML,Mund JA,Mead LE, et al. Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential[J]. Cytometry A, 2010, 77(9): 831-839.
[3]	Stou BR,Migliorini C,Kadambi A, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tu-mors: implications for antiangiogenic tihrapy [J]. Blood, 2003, 102(7): 2555-2561.
[4]	厉倩,洪茂,谭龙益, 等. 循环内皮祖细胞计数在肝细胞肝癌中的临床意义[J]. 中国肿瘤生物治疗杂志, 2011, 18(5): 548-551.
[5]	Nowak K,Rafat N,Belle S, et al. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease [J]. Eur J Cardiothorac Surg, 2010, 37(4): 758-763.
[6]	Vizio B,Novarino A,Giacobino A, et al. Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results [J]. Cancer Sci, 2010, 101(11): 2448-2454.
[7]	许良中. 乳腺病理学[M]. 上海: 上海医科大学出版社, 1999: 359.
[8]	Asahara T,Murohara T,Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis [J]. Science, 1997, 275(5302): 964-967.
[9]	Hristor M,Erl W,Weber PC, et al. Endothelial progenitor cells: isolation and characterization [J]. Trends Cardiovasc Med, 2003, 13(5): 201-206.
[10]	Fadini GP,Coracina A,Baesso I, et al. Peripheral blood CD34＋KDR＋ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population [J]. Stroke, 2006, 37(9): 2277-2282.
[11]	Liu P,Zhou B,Gu D, et al. Endothelial progenitor cell therapy in atherosclerosis: a double-edged sword? [J]. Ageing Res Rev, 2009, 8(2): 83-93.
[12]	Cerezo AB,Hornedo-Ortega R,álvarez-Fernández MA, et al. Inhibition of VEGF-induced VEGFR-2 activation and HUVEC migration by melatonin and other bioactive indolic compounds [J]. Nutrients, 2017, 9(3): E249.
[13]	周斌,刘世伟,高国璇, 等. 2016年NCCN乳腺癌临床实践指南(第1版)更新与解读[J]. 中国实用外科杂志, 2016, 36(10): 1066-1072.
[14]	Rafii S,Lyden D,Benezra R, et al. Vascular and hematopoietic stem cells: novel targets for anti-angiogenesis therapy? [J]. Nat Rev Cancer, 2002, 2(11): 826- 835.
[15]	Hagensen MK,Shim J,Thim T, et al. Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis [J]. Circulation, 2010, 121(7): 898-905.
[16]	Steurer M,Kern J,Zitt M, et al. Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry [J]. BMC Res Notes, 2008, 1: 71.
[17]	Crisa L,Cirulli V,Smith K, et a1. Human cord blood progenitors sustain thymic T-cell development and a novel form of angiogenesis [J]. Blood, 1999, 94(11): 3928-3940.
[18]	Timmermans F,Plum J,Yöder MC, et al. Endothelial progenitor cells: identity defined? [J]. J Cell Mol Med, 2009, 13(1): 87-102.
[19]	刘隽炜. 内皮祖细胞研究进展[J]. 心血管病学进展, 2011, 32(4): 528-531.
[20]	Yoder MC. Endothelial progenitor cell: a blood cell by many other names may serve similar functions[J]. J Mol Med (Berl), 2013, 91(3): 285-295.
[21]	Nowak K,Jachol N,Rafat N, et al. Alterations of circulating bone marrow-derived VEGFR-2＋ progenitor cells in isolated limb perfusion with or without rhTNF-α[J]. Ann Surg Oncol, 2013, 20(11): 3694-3701.
[22]	Murohara T,Ikeda H,Duan J, et a1. Transplanted cord blood—derived endothelial precursor cells augment postnatal neovascularization [J]. J Clin Invest, 2000, 105(11): 1527-1536.
[23]	Yang B,Gu W,Peng B, et al. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth in patients with renal cell carcinoma [J]. J Urol, 2012, 188(6): 2055-2061.

临床病理特征		例数	EPCs阳性[例(%)]	检验值	P值
年龄		?	?	?	?
?	<50岁	23	2(8.7)	?	1.000^a
?	≥50岁	47	6(12.8)	?	?
淋巴结转移		?	?	?	?
?	有	46	5(10.9)	?	1.000^a
?	无	24	3(12.5)	?	?
ER		?	?	?	?
?	阳性	46	6(13.0)	?	0.760^a
?	阴性	24	2(8.3)	?	?
PR		?	?	?	?
?	阳性	48	7(14.6)	?	0.420^a
?	阴性	22	1(4.5)	?	?
HER-2		?	?	?	?
?	阳性	23	2(8.7)	?	1.000^a
?	阴性	47	6(12.8)	?	?
临床分期		?	?	?	?
?	Ⅰ	23	4(17.4)	?	?
?	Ⅱ	21	2(9.5)	χ²＝1.121	0.806^a
?	Ⅲ	12	1(8.3)	?	?
?	Ⅳ	14	1(7.1)	?	?

临床病理特征		例数	EPCs阳性[例(%)]	检验值	P值
年龄		?	?	?	?
?	<50岁	23	2(8.7)	?	1.000^a
?	≥50岁	47	6(12.8)	?	?
淋巴结转移		?	?	?	?
?	有	46	5(10.9)	?	1.000^a
?	无	24	3(12.5)	?	?
ER		?	?	?	?
?	阳性	46	6(13.0)	?	0.760^a
?	阴性	24	2(8.3)	?	?
PR		?	?	?	?
?	阳性	48	7(14.6)	?	0.420^a
?	阴性	22	1(4.5)	?	?
HER-2		?	?	?	?
?	阳性	23	2(8.7)	?	1.000^a
?	阴性	47	6(12.8)	?	?
临床分期		?	?	?	?
?	Ⅰ	23	4(17.4)	?	?
?	Ⅱ	21	2(9.5)	χ²＝1.121	0.806^a
?	Ⅲ	12	1(8.3)	?	?
?	Ⅳ	14	1(7.1)	?	?

临床病理特征		例数	CD34、CD133、VEGFR-2表达量(%)	t值	P值
疾病分期		?	?	?	?
?	Ⅰ期	4	0.300±0.162	4.640	0.004
?	Ⅱ～Ⅳ期	4	1.130±0.318	?	?
淋巴结转移		?	?	?	?
?	是	4	1.062±0.424	2.700	0.040
?	否	4	0.370±0.287	?	?

临床病理特征		例数	CD34、CD133、VEGFR-2表达量(%)	t值	P值
疾病分期		?	?	?	?
?	Ⅰ期	4	0.300±0.162	4.640	0.004
?	Ⅱ～Ⅳ期	4	1.130±0.318	?	?
淋巴结转移		?	?	?	?
?	是	4	1.062±0.424	2.700	0.040
?	否	4	0.370±0.287	?	?

Please choose a citation manager

Content to export